Our State-of-the-Art Review on Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses is now out on @JACCCardioOncology @JACCJournals 👇. Role of current multimodality imaging and future directions for their applications:.👥For

RT @CJCJournals: 🔓 For a limited time until August 16, we are offering free promotional access to a new article in #CJC! 🌐.This study links….

🎯New Review Highlights Adipose Tissue Drug Targets. Epicardial & perivascular adipose tissues (EAT & PVAT) are emerging as key players in cardiovascular disease -and now, as promising drug targets.🫀💊. This review dives into:.✅ DPP4, GLP-1R, SGLT-2i advances.✅ AT-specific

RT @PowerfulMedical: 🔥 Published this month: Three NEW external validation studies all point to one conclusion: AI can detect acute coronar….

RT @iheartfunction: 💊 Can acetazolamide speed up decongestion in acute heart failure with volume overload?. The ADVOR trial explored the ef….

🎯 Meta-analysis to provide the NNT and efficacy of GLP-1RA in reducing risk of myocardial infarction (MI). 👥109,846 pts from 25 studies. Risk-reduction effect of GLP-1RA were pooled using pairwise meta-analysis with a random-effects model. The primary outcome was MI, and

🫀 Cardiometabolic HFpEF phenotype (cmHFpEF) is rising fast, linked to obesity, hypertension, and chronic inflammation. 🔬 New insights reveal how metabolic stress, immune shifts, and epigenetic changes drive this condition. 🧬 Targeting metabolism, inflammation & chromatin

RT @iheartfunction: Delayed GDMT up-titration in HFrEF?.This new study selected by @IzaUchmanowicz in the European Heart Journal combines a….

🎯To evaluate the relationship between CMR-imaging and pro-fibrotic/inflammatory serum biomarkers, to discriminate HFpEF from associated comorbid conditions. 👥Prospective cohort study of 35 obese participants (mean age 64 ± 8 yrs, 23% females), including:.- 16 with T2DM.- 13

RT @FeliceGragnano: Prevention of #AFib with SGLT2-I across the spectrum of cardiovascular disorders: a meta-analysis of RCTs 📊. 🔗 https://….

RT @iheartfunction: 🚫Therapeutic impasse? Not anymore. Refractory heart failure is becoming a catalyst for change — in strategy, in collabo….

🔥Proud to share that #CardiovascularDiabetology has achieved a new Impact Factor of 10.6 - its highest since 2009 - reinforcing its position among the leading journals in the Cardiovascular and Endocrinology & Metabolism fields. 🎯The journal now ranks 14th out of 230 in the

💊#SGLT2i have emerged as potential cardioprotective agents, reducing cardiovascular mortality and improving #HF outcomes. 🎯Recent evidence suggests that SGLT2i exert anti-inflammatory effects, particularly through modulating the #inflammasome pathway. 🔥This review explores

🎯To evaluate the impact of #SGLT2i on the risk of acute kidney injury (AKI) in #T2DM pts w/ severe #AS undergoing #TAVI. 👥 Multicenter Registry of consecutive pts stratified by the presence of CKD and anti-diabetic therapy (2021-2024). 🔥Our main findings were: .- SGLT2i

RT @iheartfunction: GDMT and LVEF: from static measure to trajectories of change. Journal Club review📷 The clinica….

🚨We're thrilled to launch Cardiovascular Diabetology’s #KnowTheAuthors project - giving visibility to the brilliant minds behind the science!. 🎥 First up: Maria Barranco-Altirriba presents key insights from her study on lipidomics and subclinical carotid atherosclerosis in T2D

Proud of the amazing Teamwork by the entire Cardiology Team at #AziendaOspedalieraSantAndrea for the two Live Cases broadcast globally during #EuroPCR2025. This is a significant recognition of the teamwork, expertise, and innovation we bring to patient care every day!! 🔥🔥🔥

🥳Welcome to our New Associate Editors for #CardiovascularDiabetology - @BioMedCentral . ⭐️Dr. Idit Goldfracht, PhD.Columbia University, New York City, USA. Expertise: Tissue engineering, stem cells, cardiovascular disease, 3D printing, biomaterials, vascularized 3D tissues,